Address
250 East Grand Avenue
South San Francisco, CA 94080
United States of America (the)
Phone
650 338 3533
Website
Sector
Healthcare
Industry
Biotechnology
Employees
130
First IPO Date
October 25, 2024
| Name | Title | Pay | Year Born |
| Jeffrey T. Finer | Co-Founder, Chief Executive Officer & Director | 1.04M | 1967 |
| Samira Shaikhly | Chief People Officer | 536,487 | 1970 |
| Gilbert Labrucherie | Chief Financial Officer | 711,727 | 1972 |
| Elizabeth Bhatt | President & Chief Operating Officer | 735,000 | 1968 |
| Mark A. Wilson | Chief Legal Officer | 0 | 1972 |
| George Xu | Senior Director of Corporate Development & Portfolio Strategy | 0 | N/A |
| Arthur Christopoulos BPHARM | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 0 | N/A |
| Robert J. Lefkowitz | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 0 | 1944 |
| Richard Hansen | Vice President of Technology | 0 | N/A |
| Patrick Sexton | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 0 | N/A |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.